Aim immunotech reports first quarter financial results and provides pipeline update

– continued execution across pipeline positions aim to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – lead clinical program, phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter
AIM Ratings Summary
AIM Quant Ranking